Sotatercept at 0.7 mg/kg subcutaneous every 3 weeks optimally balanced efficacy and safety for those with PAH. Sotatercept, a practice-changing therapy for pulmonary arterial hypertension (PAH), ...
Pirfenidone use was independently associated with reduced lung cancer risk in both the main cohort (aHR, 0.347) and the validation cohort (aHR, 0.716). Pirfenidone is associated with a decreased risk ...
Risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load. One of the most serious post-PE syndromes is CTEPH. A large variation in the rate of CTEPH ...
Moderate alcohol consumption and eating oily fish, fruits, and cereals may reduce the risk for rheumatoid arthritis. HealthDay News —Moderate alcohol consumption and eating oily fish, fruits, and ...
Drew Harris, MD (left), visits retired coal miner Paul White at his home in Evarts, Kentucky. White, 62, has progressive massive fibrosis. (Photo courtesy of Drew Harris) The incidence of so-called ...
Antibiotic use was not associated with increased risks for dementia, cognitive impairment/no dementia, or subsequent declines in cognitive scores compared with nonuse. HealthDay News — Any or repeated ...
The move comes on the heels of a Louisiana resident being hospitalized with bird flu (H5N1), the first severe case confirmed in the United States. HealthDay News — California Gov. Gavin Newsom ...
Researchers found that higher exposure to NO2, PM10, and PM2.5 was associated with a higher incidence of all-cause, cardiovascular, respiratory, and infectious hospital admissions. HealthDay News — ...
Improvement in PaCO2 after 3 rounds of PPV predicted ARDS survival, but to a lesser degree than improvement in the PF ratio. Investigators explored the relationship between ARDS survival and ...
Patients with obstructive sleep apnea (OSA) undergoing procedural sedation in ambulatory settings were over 3 times as likely to require airway maneuvers/interventions than those without OSA. People ...
According to Celltrion, Steqeyma is expected to be available in February 2025. Steqeyma, formerly known as CT-P43, is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate ...
Concentrations of 3 to 12 μg/mL and 12 to 35 μg/mL (about 3 to 12 and 12 to 35 glasses/month of wine) were associated with lower cardiovascular disease risk, 0.62 and 0.50, respectively. HealthDay ...